ReviewCancers2022
Clinical Considerations for Immunoparesis in Multiple Myeloma.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Increased Risk of Infections and Mortality Following Fractures in Multiple Myeloma: A Nationwide Population-Based Retrospective Cohort Study.Health science reports · 2026Article
- Association Between Natural Killer Cell Subsets (CD56bright and CD56dim) and Infectious Complications in Newly Diagnosed Multiple Myeloma (NDMM) Patients.Current issues in molecular biology · 2026Article
- Balancing Efficacy and Safety in Multiple Myeloma Patients Receiving B cell Maturation Antigen-Directed CAR T-Cell Therapy.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Impact of Qualitative and Quantitative Immunoparesis on Early Infection Risk in Patients with Newly Diagnosed Multiple Myeloma.Mediterranean journal of hematology and infectious diseases · 2026Article
- Editorial: Understanding and controlling adverse effects in myeloma patients treated with T cell redirecting immunotherapies.Frontiers in immunology · 2026Article
- Multi-omics profiling and AI-driven clinically deployable risk models in MGUS and smoldering myeloma.Clinical and experimental medicine · 2025Review
- Exploring the depths of hypogammaglobulinemia in lymphoid malignancies: Pathophysiology, clinical implications, management options, and future directions.Blood reviews · 2025Review
- Environmental and occupational risk factors associated with multiple myeloma: a multicenter, hospital-based, matched case-control study.BMC public health · 2025Article
- Absence of Red Blood Cell Alloimmunization in Transfused Patients Receiving Daratumumab: Experience from a Single Center.Journal of clinical medicine · 2025Article
- Monoclonal gammopathy in WHIM syndrome can mask hypogammaglobulinemia.The journal of allergy and clinical immunology. Global · 2025Article
- Immunoparesis in multiple myeloma: a current overview.Frontiers in oncology · 2025Review
- Secondary antibody deficiencies: what's around the corner?Frontiers in immunology · 2025Review
- Lymphocyte profile in peripheral blood of patients with multiple myeloma.Annals of hematology · 2024Article
- Review
- Multiple myeloma.Nature reviews. Disease primers · 2024Review
- Design, synthesis, and activity evaluation of 2-iminobenzimidazoles as c-Myc inhibitors for treating multiple myeloma.Heliyon · 2024Article
- Bad players in AL amyloidosis in the current era of treatment.Expert review of hematology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma is a relatively common clonal plasma cell disorder, comprising 17% of hematologic malignancies. One of the hallmark features of this disease is immunoparesis, which is characterized by the suppression of immunoglobulin polyclonality. Though not entirely elucidated, the mechanism behind this process can be attributed to the changes in the tumor microenvironment. All treating clinicians must consider potential complications related to immunoparesis in the management of multiple myeloma. Though not explicitly described in large data series, the increased risk of infection in multiple myeloma is likely, at least in part, due to immunoglobulin suppression. Additionally, the presence of immunoparesis serves as a prognostic factor, conveying poorer survival and a higher risk of relapse. Even in the era of novel agents, these findings are preserved, and immunoglobulin recovery also serves as a sign of improved outcome following autologous HSCT. Though not within the diagnostic criteria for multiple myeloma, the presence and degree of immunoparesis should be at diagnosis for prognostication, and immunoglobulin recovery should be tracked following myeloablative therapy and autologous HSCT.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.